Efficacy and Safety of ASF 1057 Cream 0.5% in the Treatment of Seborrhoeic Dermatitis: A Phase III Randomised, Double-Blind, Vehicle and Placebo Controlled, Parallel Groups, Multi-Centre Trial.
Latest Information Update: 14 Jan 2020
At a glance
- Drugs ASF 1057 (Primary)
- Indications Seborrhoeic dermatitis
- Focus Therapeutic Use
- Sponsors Astion Pharma A/S
Most Recent Events
- 19 May 2014 New trial record